Pleiotropic Effects of Nifedipine on Atherosclerosis

Author(s): Sho-ichi Yamagishi, Kazuo Nakamura, Katsuhiko Takenaka, Takanori Matsui, Hiroyoshi Inoue

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 12 , 2006

Become EABM
Become Reviewer


Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatoryfibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.

Keywords: insulin resistance, diabetes, atherosclerosis, Advanced glycation end products, oxidative stress, nitric oxide

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1543 - 1547]
Pages: 5
DOI: 10.2174/138161206776389877
Price: $65

Article Metrics

PDF: 2